 Home > Biochemistry News > Biotechnology News > Significantly reduce the level of tau protein AD antisense oligonucleotide therapy announced Phase 1 clinical data

Significantly reduce the level of tau protein AD antisense oligonucleotide therapy announced Phase 1 clinical data

 Last Update: 2021-08-05
 Source: Internet
 Author: User

Tags

1 8 gram

weeks

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On July 26, Biogen and Ionis Pharmaceuticals announced that the antisense oligonucleotide (ASO) therapy BIIB080/IONIS-MAPTRx jointly developed by the two parties was used in patients with mild Alzheimer’s disease (AD).

BIIB080 is an ASO therapy jointly developed by Bojian and Ionis, which binds to the mRNA encoding tau protein, which leads to the degradation of mRNA and the decrease of tau protein level

In patients treated with BIIB080, 8 weeks after the last dose (day 141), the total tau protein concentration in the cerebrospinal fluid showed a dose-dependent decrease.

Note: The original text has been deleted

Reference materials:

[1] Biogen and Ionis report positive topline clinical data on investigational Alzheimer's disease treatment at AAIC.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.